TY - JOUR
T1 - Clinical manifestations of familial medullary thyroid carcinoma
AU - Kameyama, Kaori
AU - Okinaga, Hiroko
AU - Takami, Hiroshi
PY - 2004/6
Y1 - 2004/6
N2 - We conducted a large-scale nation-wide questionnaire survey to ascertain the status of familial medullary thyroid carcinoma (MTC) in Japan in 2002. Out of a total of 271 MTC cases (male to female ratio 1:1.4), multiple endocrine neoplasia (MEN) 2A accounted for 83 cases (30.6%), familial MTC (FMTC) for 14 cases (5.1%), MEN for 11 cases (4.1%), and sporadic MTC for 163 cases (60.1%). Mean age at the time of diagnosis was 35.6 in MEN2A, 34.6 in FMTC, 30.5 in MEN2B, and 47.6 in sporadic MTC. Forty-five percent of MEN2A patients had pheochromocytoma and 11% of MEN2A patients had parathyroid disorders when MTC was diagnosed. Finally, the RET oncogene test yielded the largest number of initial findings that led to diagnosis of familial MTC.
AB - We conducted a large-scale nation-wide questionnaire survey to ascertain the status of familial medullary thyroid carcinoma (MTC) in Japan in 2002. Out of a total of 271 MTC cases (male to female ratio 1:1.4), multiple endocrine neoplasia (MEN) 2A accounted for 83 cases (30.6%), familial MTC (FMTC) for 14 cases (5.1%), MEN for 11 cases (4.1%), and sporadic MTC for 163 cases (60.1%). Mean age at the time of diagnosis was 35.6 in MEN2A, 34.6 in FMTC, 30.5 in MEN2B, and 47.6 in sporadic MTC. Forty-five percent of MEN2A patients had pheochromocytoma and 11% of MEN2A patients had parathyroid disorders when MTC was diagnosed. Finally, the RET oncogene test yielded the largest number of initial findings that led to diagnosis of familial MTC.
KW - Familial cancer
KW - Medullary thyroid carcinoma
KW - RET protooncogene
UR - http://www.scopus.com/inward/record.url?scp=3242692440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242692440&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2004.05.002
DO - 10.1016/j.biopha.2004.05.002
M3 - Article
C2 - 15271414
AN - SCOPUS:3242692440
SN - 0753-3322
VL - 58
SP - 348
EP - 350
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
IS - 6-7
ER -